Invesco Ltd. Sells 1,368 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Invesco Ltd. lessened its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 3.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 38,944 shares of the medical research company's stock after selling 1,368 shares during the quarter. Invesco Ltd. owned approximately 0.14% of Bio-Rad Laboratories worth $12,793,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in BIO. Metis Global Partners LLC boosted its holdings in shares of Bio-Rad Laboratories by 4.4% during the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock worth $234,000 after buying an additional 30 shares in the last quarter. Signaturefd LLC boosted its position in shares of Bio-Rad Laboratories by 13.2% during the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock worth $87,000 after purchasing an additional 31 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after buying an additional 32 shares during the period. Thrivent Financial for Lutherans raised its stake in Bio-Rad Laboratories by 0.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock worth $1,488,000 after buying an additional 32 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its holdings in Bio-Rad Laboratories by 3.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after acquiring an additional 34 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on BIO. Wells Fargo & Company decreased their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $380.20.

Bio-Rad Laboratories Stock Down 3.0 %

BIO traded down $7.52 during mid-day trading on Friday, reaching $242.22. 377,689 shares of the stock were exchanged, compared to its average volume of 317,205. Bio-Rad Laboratories, Inc. has a 1 year low of $215.38 and a 1 year high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock has a market capitalization of $6.78 billion, a PE ratio of -3.72 and a beta of 1.12. The company has a 50 day moving average price of $251.03 and a two-hundred day moving average price of $308.49.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.